ARPANSA is working with the International Atomic Energy Agency (IAEA) and dosimetry auditors globally to develop a world first film dosimetry intercomparison tool.
Illegal laser pointers that are being imported into the country due to incorrect product labelling is an issue being pinpointed to Australia’s Freight and Trade Alliance this month by ARPANSA scientist Dr Chris Brzozek.
ARPANSA has provided funding to RMIT to investigate the impact of non-ionising radiation on cell permeability. This research is funded as the first ‘major project’ under ARPANSA’s new EME Program Research Framework.
ARPANSA experts have published an article in Public Health Research and Practice, a journal of the Sax Institute, that calls for more research into the use of non-ionising radiation for cosmetic purposes.
The Australian Government announces the appointment of Dr Gillian Hirth as Chief Executive Officer (CEO) of ARPANSA following the retirement of current CEO, Dr Carl-Magnus Larsson.
ARPANSA has issued a licence to the Australian Nuclear Science and Technology Organisation (ANSTO) to prepare a site for the Intermediate Level Waste Capacity Increase (ILWCI) facility.
Dose accuracy is critical to safe cancer treatment. Dosimetry audits provide assurance that the radiation dose delivered to the patient aligns with the planned dose.
ARPANSA and the Cancer Council of Victoria have advised Australians to avoid using aerosol sunscreens and stick with creams and lotions for UV protection.
In another world first, ARPANSA and Swinburne University have joined forces to produce a systematic map of the scientific evidence into the impact of radio waves on the environment.
The Australian Radiation Protection and Nuclear Safety Agency has partnered with the Republic of the Marshall Islands (RMI) government to support the development of a sovereign radiation monitoring capability in the region.
